Nvidia(US:NVDA) Zheng Quan Shi Bao·2025-06-12 04:53Core Viewpoint - The recent performance of global technology stocks, particularly Nvidia, indicates a potential rebound in the tech sector, with Nvidia's stock price rising significantly and its market capitalization nearing $3.5 trillion, reclaiming its position as the world's most valuable company [1][3]. Group 1: Nvidia's Performance - Nvidia's stock price has increased over 24% in May and nearly 6% since June, approaching its historical high [1]. - As of the latest data, Nvidia's market capitalization is approximately $3.49 trillion [2]. Group 2: AI Development Initiatives - Nvidia's CEO announced plans to establish AI technology centers in seven European countries and build over 20 large AI factories in Europe, aiming to enhance AI computing power tenfold by 2026 [3]. - The announcement has led to a surge in related sectors in the A-share market, with significant gains in quantum technology, CPO, and AI glasses concepts [3]. Group 3: Market Sentiment and Recovery - Analysts from Xinyi Securities suggest capitalizing on the recovery window for the tech sector in June, noting that growth stocks are showing signs of upward movement from their lows [4]. - The positive sentiment is supported by favorable non-farm employment data, which alleviated concerns about a slowing U.S. economy [4]. Group 4: Stock Performance and Growth Potential - Several tech stocks have shown remarkable rebounds, with some, like Shenghong Technology, seeing their stock prices increase by nearly 155% this year [5]. - A list of high-growth tech stocks with strong earnings potential has been compiled, focusing on those with a return on equity (ROE) exceeding 10% for three consecutive years and a projected net profit growth rate above 20% [9][11]. Group 5: Notable Stock Movements - New Yi Sheng's stock price surged from below 50 to above 100 in just two months, while Shi Jia Photon rose from below 13 to a peak of over 36 [6]. - Stocks like Huihan Technology and Huqin Technology have seen significant price corrections, with declines exceeding 30% from their yearly highs [10].